Table 3.

Common adverse events reported by 3 trials conducted on avatrombopag.

Adverse events	Adverse events reported from 3 selected studies
	Terrault et al62								Terrault et al63									Kuter and Allen73
	ADAPT-1				ADAPT-2				Cohort A						Cohort B			Multiple dose
	Low-baseline platelet count		High-baseline platelet count		Low-baseline platelet count		High-baseline platelet count		Placebo (n = 16)	20 mg (n = 18)	40 mg (n = 16)	80 mg (n = 17)	Placebo (n = 21)	10 mg (n = 21)	20 mg (n = 21)	Placebo (n = 21)	1 mg (n = 6)	3 mg (n = 6)	10 mg (n = 6)	20 mg (n = 6)	50 mg (n = 6)	75 mg (n = 6)	100 mg (n = 6)
	Placebo (n = 48)	AVP 60 mg (n = 89)	Placebo (n = 32)	AVP 40 mg (n = 58)	Placebo (n = 43)	AVP 60 mg (n = 70)	Placebo (n = 33)	AVP 40 mg (n = 57)
Patients with any TEAEs	31 (64.6%)	53 (59.6%)	18 (56.25%)	31 (53.4%)	22 (51.2%)	36 (51.4%)	15 (45.5%)	28 (49.12%)	12 (75%)	17 (94.4%)	13 (81.3%)	13 (76.5%)	16 (76.2%)	17 (81.0%)	18 (85.7%)	7 (33.3%)	2 (33.3%)	1 (16.7%)	2 (33.3%)	1 (16.7%)	1 (16.7%)	2 (33.3%)	2 (33.3%)
Drug therapy-related TEAEs	7 (14.6%)	12 (13.5%)	2 (6.3%)	4 (6.9%)	9 (20.9%)	6 (8.6%)	2 (6.1%)	4 (7.0%)	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgeusia	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2 (9.5%)	1 (16.7%)	1 (16.7%)	1 (16.7%)	1 (16.7%)	0	1 (16.7%)	1 (16.7%)
Flatulence	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2 (9.5%)	1 (16.7%)	0	0	0	0	0	(16.7%)
Diarrhea	1 (2.1%)	4 (4.5%)	2 (6.3%)	1 (1.7%)	3 (7.0%)	3 (4.3%)	0	2 (3.5%)	0	2 (11.1%)	1 (6.3%)	1 (5.9%)	2 (9.5%)	0	3 (14.3%)	1 (4.8%)	0	0	0	0	0	0	(16.7%)
Headache	3 (6.3%)	5 (5.6%)	2 (6.3%)	6 (10.3%)	4 (9.3%)	2 (2.9%)	1 (3.0%)	2 (3.5%)	2 (12.5%)	2 (11.1%)	2 (12.5%)	1 (5.9%)	3 (14.3%)	1 (4.8%)	3 (14.3%)
Somnolence	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1 (4.8%)	0	0	0	1 (16.7%)	1 (16.7%)	0	0
Nausea	2 (4.2%)	4 (4.5%)	2 (6.3%)	5 (8.6%)	5 (11.6%)	6 (8.6%)	6 (8.6%)	3 (5.3%)	2 (12.5%)	1 (5.6%)	2 (12.5%)	2 (11.8%)	3 (14.3%)	5 (23.8%)	2 (9.5%)	1 (4.8%)	0	1 (16.7)	0	0	0	0	0
Vomiting	–	–	–	–	–	–	–	–	0	1 (5.6%)	2 (12.5%)	3 (17.6%)	1 (4.8%)	0	1 (4.8%)	–	–	–	–	–	–	–	–
Lethargy	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0	1 (16.7%)	0	0	0	0
Muscle contraction	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0	0	0	0	0	1 (16.7%)
Portal hypertensive gastropathy	–	–	–	–	–	–	–	–	0	4 (22.2%)	2 (12.5%)	0	2 (9.5%)	3 (14.3%)	0
Abdominal pain	3 (6.3%)	8 (9.0%)	3 (9.4%)	6 (10.3%)	3 (7.0%)	2 (2.9%)	1 (3.0%)	2 (3.5%)	0	4 (22.2%)	1 (6.3%)	1 (5.9%)	3 (14.3%)	2 (9.5%)	0
Fatigue	1 (2.1%)	6 (6.7%)	1 (3.1%)	1 (1.7%)	3 (7.0%)	1 (1.4%)	0	2 (3.5%)	1 (6.3%)	4 (22.2%)	1 (6.3%)	0	4 (19%)	2 (9.5%)	2 (9.5%)
Edema peripheral	2 (4.2%)	3 (3.4%)	1 (3.1%)	3 (5.2%)	2 (6.1%)	0	3 (9.1%)	0	–	–	–	–	–	–	–
Pyrexia	6 (12.5%)	7 (7.9%)	2 (6.3%)	5 (8.6%)	2 (4.7%)	11 (15.7%)	4 (12.1)	4 (7.0%)	2 (12.5%)	0	0	2 (11.8%)	3 (14.3%)	1 (4.8%)	0
Dyspepsia	2 (4.2)	0	2 (6.3)	0	0	–	–	–	2 (12.5)	0	0	2 (11.8%)	3 (14.3%)	1 (4.8%)	0
Dizziness	–	–	–	–	3 (7.0%)	3 (4.3%)	1 (3.0%)	0	1 (6.3%)	2 (11.1%)	0	1 (5.9%)	1 (4.8%)	3 (14.3%)	1 (4.8%)

Abbreviation: TEAEs indicate treatment-emergent adverse events; AVP -avatrombopag.